mBio (Oct 2021)
Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants
- Linda van Oosten,
- Jort J. Altenburg,
- Cyrielle Fougeroux,
- Corinne Geertsema,
- Fred van den End,
- Wendy A. C. Evers,
- Adrie H. Westphal,
- Simon Lindhoud,
- Willy van den Berg,
- Daan C. Swarts,
- Laurens Deurhof,
- Andreas Suhrbier,
- Thuy T. Le,
- Shessy Torres Morales,
- Sebenzile K. Myeni,
- Marjolein Kikkert,
- Adam F. Sander,
- Willem Adriaan de Jongh,
- Robert Dagil,
- Morten A. Nielsen,
- Ali Salanti,
- Max Søgaard,
- Timo M. P. Keijzer,
- Dolf Weijers,
- Michel H. M. Eppink,
- René H. Wijffels,
- Monique M. van Oers,
- Dirk E. Martens,
- Gorben P. Pijlman
Affiliations
- Linda van Oosten
- Laboratory of Virology, Wageningen University, Wageningen, The Netherlands
- Jort J. Altenburg
- Bioprocess Engineering, Wageningen University, Wageningen, The Netherlands
- Cyrielle Fougeroux
- AdaptVac Aps, Hørsholm, Denmark
- Corinne Geertsema
- Laboratory of Virology, Wageningen University, Wageningen, The Netherlands
- Fred van den End
- Bioprocess Engineering, Wageningen University, Wageningen, The Netherlands
- Wendy A. C. Evers
- Bioprocess Engineering, Wageningen University, Wageningen, The Netherlands
- Adrie H. Westphal
- Laboratory of Biochemistry, Wageningen University, Wageningen, the Netherlands
- Simon Lindhoud
- Laboratory of Biochemistry, Wageningen University, Wageningen, the Netherlands
- Willy van den Berg
- Laboratory of Biochemistry, Wageningen University, Wageningen, the Netherlands
- Daan C. Swarts
- Laboratory of Biochemistry, Wageningen University, Wageningen, the Netherlands
- Laurens Deurhof
- Laboratory of Phytopathology, Wageningen University, Wageningen, The Netherlands
- Andreas Suhrbier
- QIMR Berghofer Medical Research Institute, Brisbane, Australia
- Thuy T. Le
- QIMR Berghofer Medical Research Institute, Brisbane, Australia
- Shessy Torres Morales
- Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands
- Sebenzile K. Myeni
- Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands
- Marjolein Kikkert
- Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands
- Adam F. Sander
- AdaptVac Aps, Hørsholm, Denmark
- Willem Adriaan de Jongh
- AdaptVac Aps, Hørsholm, Denmark
- Robert Dagil
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Morten A. Nielsen
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Ali Salanti
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
- Max Søgaard
- ExpreS2ion Biotechnologies Aps, Hørsholm, Denmark
- Timo M. P. Keijzer
- Applikon Biotechnology BV, Delft, The Netherlands
- Dolf Weijers
- Laboratory of Biochemistry, Wageningen University, Wageningen, the Netherlands
- Michel H. M. Eppink
- Bioprocess Engineering, Wageningen University, Wageningen, The Netherlands
- René H. Wijffels
- Bioprocess Engineering, Wageningen University, Wageningen, The Netherlands
- Monique M. van Oers
- Laboratory of Virology, Wageningen University, Wageningen, The Netherlands
- Dirk E. Martens
- Bioprocess Engineering, Wageningen University, Wageningen, The Netherlands
- Gorben P. Pijlman
- ORCiD
- Laboratory of Virology, Wageningen University, Wageningen, The Netherlands
- DOI
- https://doi.org/10.1128/mBio.01813-21
- Journal volume & issue
-
Vol. 12,
no. 5
Abstract
Vaccines pave the way out of the SARS-CoV-2 pandemic. We have developed a virus-like particle (VLP)-based vaccine using the baculovirus-insect cell expression system, a robust production platform known for its scalability, low cost, and safety. Baculoviruses were constructed encoding SARS-CoV-2 spike proteins: full-length S, stabilized secreted S, or the S1 domain. This two-component nanoparticle vaccine can now be further developed to help alleviate the burden of COVID-19.
